Over the last 7 days, the United States market has risen by 1.2%, contributing to a substantial increase of 35% over the past year, with earnings expected to grow by 15% per annum in the coming years. In this favorable market environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive trends.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 253 stocks from our US High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Trade Desk

Simply Wall St Growth Rating: ★★★★★☆

Overview: The Trade Desk, Inc. is a technology company that provides a global advertising platform for buyers to create, manage, and optimize digital advertising campaigns across various channels, with a market cap of approximately $58.05 billion.

Operations: Trade Desk generates revenue primarily from its software and programming segment, amounting to $2.17 billion. The company operates both in the United States and internationally, focusing on providing technology solutions for digital advertising campaigns.

Trade Desk's recent performance underscores its robust position in the digital advertising sector, with a notable 95.9% earnings growth over the past year outpacing the media industry's 17%. This growth trajectory is supported by significant R&D investments, aligning with a revenue increase from $464.25 million to $584.55 million in Q2 2024 alone. The company's strategic initiatives, including partnerships like the one with Admiral integrating OpenPass for enhanced user authentication, demonstrate its commitment to innovation and addressing industry challenges such as consumer privacy and ad addressability. With earnings expected to surge by 30.82% annually, Trade Desk is not only adapting but also actively shaping future market dynamics.

• Get an in-depth perspective on Trade Desk's performance by reading our health report here.

• Explore historical data to track Trade Desk's performance over time in our Past section.

Autodesk

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Autodesk, Inc. offers 3D design, engineering, and entertainment technology solutions globally with a market capitalization of approximately $62.19 billion.

Operations: The primary revenue stream for Autodesk comes from its CAD/CAM software segment, which generated $5.81 billion. The company focuses on providing advanced solutions in design and engineering technology across various industries worldwide.

Autodesk's strategic focus on integrating advanced technologies into its offerings is evident from its recent alliances, notably with Esri to enhance geospatial data integration in Autodesk Forma. This move not only streamlines early design phases for AECO professionals but also leverages GIS and BIM technologies to potentially reduce project costs and timelines. Financially, Autodesk has demonstrated robust growth with a 10% annual revenue increase forecasted, outpacing the US market's 8.8%. Moreover, the firm's commitment to innovation is underscored by a significant R&D expenditure ratio of 16.1%, aligning with an anticipated earnings growth of 16.08% per year. These strategic initiatives and financial metrics highlight Autodesk’s adaptability and potential influence on future industry standards, despite facing challenges such as recent scrutiny over sales practices which could impact stakeholder confidence.

• Unlock comprehensive insights into our analysis of Autodesk stock in this health report.

• Understand Autodesk's track record by examining our Past report.

Vertex Pharmaceuticals

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing therapies for cystic fibrosis, with a market cap of approximately $125 billion.

Operations: Vertex Pharmaceuticals generates revenue primarily from its pharmaceuticals segment, amounting to $10.34 billion. The company focuses on developing and commercializing treatments specifically for cystic fibrosis.

Vertex Pharmaceuticals, while navigating a challenging financial landscape with a net loss reported in the recent quarter, shows promise with its strategic R&D investments and product pipeline. The company allocated 46.0% of its revenue to R&D, underscoring its commitment to innovation, particularly in treatments for acute pain and cystic fibrosis. Recent approvals and fast-track designations for new drugs like suzetrigine highlight Vertex's potential to meet significant unmet medical needs. Additionally, the firm has actively repurchased shares worth $883.81 million since last year, signaling confidence in its future prospects despite current profitability challenges. With revenue growth projected at 9.4% annually, slightly outpacing the US market average of 8.8%, Vertex is positioning itself as a resilient player in biotech through continuous innovation and strategic market maneuvers.

• Click here to discover the nuances of Vertex Pharmaceuticals with our detailed analytical health report.

• Evaluate Vertex Pharmaceuticals' historical performance by accessing our past performance report.

Make It Happen

• Click through to start exploring the rest of the 250 US High Growth Tech and AI Stocks now.

• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.

• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:TTD NasdaqGS:ADSK and NasdaqGS:VRTX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com